Thursday, September 22, 2022

 

09.00                   Registration Opens

​

10.00 – 10.10    Welcome Address

​

10.10 – 11.40    Plenary Symposium 1: Emerging Concepts / New Agents (including Immunometabolism)

 

10.10 – 10.40    Dissecting and modulating reactive anti-tumor immunity in human cancer 

Daniela Thommen, Amsterdam, The Netherlands

​

10.40 – 11.10    CH13L1: a novel NK cell related immune check point

          Maria Rescigno, Pieve Emanuele (Milano), Italy

 

11.10 – 11.40    Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors 

for elimination by checkpoint blockade

​

11.40 – 13.10    Plenary Symposium 2: Tumor microenvironment and microbiome

 

11.40 – 12.10    Investigating the impact of lymphatic transport in immunotherapy

                            Amanda Lund, New York, NY, USA

 

12.10 – 12.40    Immune cell communications in the tumor microenvironment

 Thorsten Mempel, Boston, MA, USA
 

12.40 – 13.10    Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment 

Romina Goldszmid, Bethesda, MD, USA

​

13.10 – 14.00    Lunch

​

14.00 – 15.00    Satellite Symposium 

​

15.00 – 15.30    Coffee Break

​

15.30 – 17.30    Plenary Symposium 3: B cells in immunooncology

 

15.30 – 16.00    From B cells to tertiary lymphoid structures in NSCLC patients

 Marie-Caroline Dieu-Nosjean, Paris, France

​

16.00 – 16.30    Neoantigen-driven B cells promote CD8 T cell responses

          Nikhil Joshi, New Haven, CT, USA

​

16.30 – 17.00    Engineering B cells for cancer treatment

          Adi Barzel, Tel Aviv, Israel

 

17.00 – 17.15    Speaker 4 – proffered paper
17.15 – 17.30    Speaker 5 – proffered paper

​

17.30                  Welcome Reception and Poster Viewing (at the venue)

​

Friday, September 23, 2022

 

08.30 – 09.30    Plenary Symposium 4: Vaccine Therapy
 

08.30 - 09.00     IDH directed vaccines in Glioblastoma

 Michael Platten, Heidelberg, Germany

​

09.00 - 09.30     The generation of immunostimulatory exosomes programmed by oncolytic viruses

 Brian Lichty, Toronto, ON, Canada

​

09.30 – 10.30    Pro & Contra Sessions for Critical Topics

 

09.30 – 10.00    Pro IO combination with chemotherapy 

          Mascha Binder, Halle, Germany

 

10.00 – 10.30    Contra: IO mono- or combo-therapy shall prevail 

          Stéphane Champiat, Villejuif, France

​

10.30 – 11.00    Coffee Break

​

11.00 – 12.00    Satellite Symposium 

​

12.00 – 13.30    Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

 

12.00 – 12.30    Single cell and spatial transcriptomics unravel a NASH-associated innate immunity contexture in 

 hepatocellular carcinoma associated with poor response to immunotherapy

 

12.30 – 13.00    Emerging Technologies to Image  Immune Cell Changes in Response to Therapy

 

13.00 – 13.15    Speaker 3 – proffered paper
13.15 – 13.30    Speaker 4 – proffered paper

​

13.30 – 14.30    Lunch

​

14.30 – 15.00    Satellite Symposium

​

15.00 – 15.45    Lifetime Achievement Award presented to Prof. Dr. Laurence Zitvogel

Microbiota-centered Interventions to circumvent primary resistance to I-O

Laurence Zitvogel, Villejuif, France

​

15.45 – 16.15     Coffee Break

​

16.15 – 17.30     Plenary Symposium 6: “Lost in Translation”

 

16.15 – 16.45     Will vaccination strategies come back of age in melanoma? 

  Tanja de Gruijl, Amsterdam, The Netherlands

 

16.45 – 17.15     What T cells see in context of immunotherapy

  Sine Reker Hadrup,  Lyngby, Denmark

 

17.15 – 17.30     Speaker 3 – proffered paper

​

17.30 – 18.30     Plenary Session 7: Young Researcher Session (from submitted abstracts)

 

17.30 – 17.45     Speaker 1 – from submitted abstracts
17.45 – 18.00     Speaker 2 – from submitted abstracts
18.00 – 18.15     Speaker 3 – from submitted abstracts
18.15 – 18.30     Speaker 4 – from submitted abstracts

 

18.30                    Poster Viewing with Presenters

​

20.00                    ITOC9 Conference Dinner

Saturday, September 24, 2022

 

08.00 – 09.00    Plenary Symposium 8: Cell Therapy in Solid Tumors

 

08.00 – 08.30    Reengineering CAR T cells for optimized efficacy in solid tumors

          Judith Feucht, Tübingen, Germany

​

08.30 – 09.00    Tuning CAR T cell for recognition of low antigen densities on solid tumors 

​

09.00 – 09.30    Satellite Symposium 

​

09.30 – 11.00    Plenary Symposium 9: Cell Therapy in Haematologic Diseases

 

09.30 – 10.00    Single-cell approach for identifying antigen dependent and independent toxicity in immunotherapies

          Caleb Lareau, Standford, CA, USA

​

10.00 – 10.30    Novel approaches to cell therapy of myeloma

          Andrea Schmidts, Boston, MA, USA
 

10.30 – 11.00    T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes

​

11.00 – 11.30    Coffee Break

​

11.30 – 12.30    Plenary Symposium 10: Combination Therapy (with a special focus on local IO)

 

11.30 – 12.00    Local low-dose RT to address anti-PD-1 resistance

12.00 – 12.30    Local immune modulation and tumor ablation

          Gosse Adema, Nijmegen, The Netherlands
 

12.30 – 12.45    Speaker 3 – proffered paper
12.45 – 13.00    Speaker 4 – proffered paper
13.00 – 13.15    Speaker 5 – proffered paper

​

13.15 – 13.30    Best Poster Awards & Closing Remarks

 

13.30 – 14.30    Lunch